Therapeutic melanoma vaccine improves response rate, progression-free survival
Thursday, June 2, 2011 - 09:00
in Health & Medicine
A vaccine for one of the most lethal cancers, advanced melanoma, has improved response rate and progression-free survival for patients when combined with the immunotherapy drug Interleukin-2, according to research led by scientists from The University of Texas MD Anderson Cancer Center and Indiana University Health Goshen Center for Cancer Care.